Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 19Terminated 5Active not recruiting 2Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Thrombocythemia, Essential 1Recurrence 1Polycythemia Vera 1Polycythemia 1Ovarian Neoplasms 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cytarabine 55Decitabine 33Azacitidine 30Idarubicin 22venetoclax 21fludarabine 16Cyclophosphamide 16Granulocyte Colony-Stimulating Factor 15Daunorubicin 12Mitoxantrone 9Etoposide 8Cladribine 8Busulfan 8Aclarubicin 8Homoharringtonine 7Filgrastim 7Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5aclacinomycins 4Tretinoin 4Sorafenib 4Radiotherapy 4Polymerase Chain Reaction 4Mycophenolic Acid 4Lenalidomide 4Gemtuzumab 4Cyclosporine 4Clofarabine 4Arsenic Trioxide 4sargramostim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Myeloid, Acute × Vorinostat × Clear all
NCT01039363 2009-12-25

Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia

Samsung Medical Center

Phase 2 Unknown
27 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡